HIV effort. More people than ever are receiving antiretroviral treatment and have viral suppression. Deaths from AIDS are at their lowest level for two decades. Yet despite this encouraging progress, ...

Advances in immunotherapy have ushered in a new era of treatment for follicular lymphoma (FL), particularly for patients who have experienced relapse ...

Gilead (GILD) announced The New England Journal of Medicine, or NEJM, published the full results from the company’s pivotal ...

The number of new HIV infections and deaths has fallen across the world, marking significant progress in the fight against ...

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure ...

The exciting prospects of harnessing Africa's medicinal plants to solve health challenges, particularly future pandemics and ...

Discover the groundbreaking results of Lenacapavir, a twice-yearly injection that reduces HIV infection risk offering an ...

Expect scattered rain showers. The low will be 66°. Moderate air quality (51-100) Primary pollutant O₃ 86 μg/m³ Amount of moisture present in the air relative to the maximum amount of moisture the air ...

Gilead Sciences demonstrated positive momentum on the NASDAQ, with shares climbing 0.6 percent to $91.88. This upward trajectory is primarily attributed to groundbreaking results from clinical trials ...

In addition, we kept open the possibility that the ETF will continue to rise and could reach around 108.45. To see how we ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) on November 25 and set a price target ...